Free tool
FAERS Monitor: Jatenzo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206089 or its brand name (Jatenzo, Testosterone Undecanoate). Reports on generic versions are filed under their own applications.
Reports
563
Serious
270
48% of reports
Hospitalization
106
Death reported
22
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use60
- drug ineffective33
- fatigue28
- blood testosterone decreased25
- headache25
- therapy interrupted25
- blood testosterone abnormal22
- intentional product use issue22
- product availability issue19
- polycythaemia16
- blood pressure increased15
- asthenia14
- blood testosterone increased14
- haematocrit increased14
- product dose omission issue14
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 3 |
| 2010 | 6 |
| 2011 | 2 |
| 2012 | 9 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 12 |
| 2016 | 7 |
| 2017 | 5 |
| 2018 | 22 |
| 2019 | 8 |
| 2020 | 19 |
| 2021 | 46 |
| 2022 | 29 |
| 2023 | 107 |
| 2024 | 106 |
| 2025 | 100 |
| 2026 | 69 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,596 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood testosterone abnormalSignal | 22 | 758.2 | 501.2 | 15,574 |
| polycythaemiaSignal | 16 | 292.0 | 179.8 | 4,320 |
| blood testosterone increasedSignal | 14 | 244.9 | 145.7 | 3,141 |
| haematocrit increasedSignal | 14 | 230.9 | 137.4 | 2,961 |
| blood testosterone decreasedSignal | 25 | 137.0 | 93.3 | 3,231 |
| product availability issueSignal | 19 | 31.2 | 20.0 | 526 |
| therapy interruptedSignal | 25 | 13.1 | 8.9 | 268 |
| intentional product use issueSignal | 22 | 9.4 | 6.2 | 157 |
| blood pressure increasedSignal | 15 | 3.7 | 2.2 | 27 |
| off label useSignal | 60 | 2.6 | 2.0 | 58 |
| product dose omission issue | 14 | 1.8 | 1.1 | 4 |
| headache | 25 | 1.5 | 1.0 | 4 |
| asthenia | 14 | 1.4 | 0.8 | 1 |
| fatigue | 28 | 1.3 | 0.9 | 2 |
| drug ineffective | 33 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.